The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
Open accessAbstract
There is a close relationship between diabetes mellitus and heart failure, and diabetes is an independent risk factor for heart failure. Diabetes and heart failure are linked by not only the complication of ischemic heart disease, but also by metabolic disorders such as glucose toxicity and lipotoxicity based on insulin resistance. Cardiac dysfunction in the absence of coronary artery disease, hypertension, and valvular disease is called diabetic cardiomyopathy. Diabetes-induced hyperglycemia and hyperinsulinemia lead to capillary damage, myocardial fibrosis, and myocardial hypertrophy with mitochondrial dysfunction. Lipotoxicity with extensive fat deposits or lipid droplets is observed on cardiomyocytes. Furthermore, increased oxidative stress and inflammation cause cardiac fibrosis and hypertrophy. Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor is currently one of the most effective treatments for heart failure associated with diabetes. However, an effective treatment for lipotoxicity of the myocardium has not yet been established, and the establishment of an effective treatment is needed in the future. This review provides an overview of heart failure in diabetic patients for the clinical practice of clinicians.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206 · cited 1×
“Empagliflozin significantly reduced the primary composite endpoint of cardiovascular death or hospitalization for worsening heart failure compared to that in the placebo group in patients with HFrEF and with or without type 2 diabetes (EMPEROR-Reduced) [86].”
BackgroundEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Elliott, P., Andersson, B., Arbustini, E., Bilinska, Z., Cecchi, F., Charron, P., Dubourg, O., Kuhl, U., Maisch, B., McKenna, W. J., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm342 · Cited by 3,010
Redfield, M. M., Jacobsen, S. J., Burnett, J. C., Mahoney, D. W., Bailey, K. R., & Rodeheffer, R. J. (2003) · JAMA · doi:10.1001/jama.289.2.194 · Cited by 3,004
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Role of diabetes in congestive heart failure: The Framingham study
Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974) · The American Journal of Cardiology · doi:10.1016/0002-9149(74)90089-7 · Cited by 2,090
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
New type of cardiomyopathy associated with diabetic glomerulosclerosis
Rubler, S., Dlugash, J., Yuceoglu, Y. Z., Kumral, T., Branwood, A. W., & Grishman, A. (1972) · The American Journal of Cardiology · doi:10.1016/0002-9149(72)90595-4 · Cited by 1,837
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity
Jia, G., Hill, M. A., & Sowers, J. R. (2018) · Circulation Research · doi:10.1161/circresaha.117.311586 · Cited by 1,807
Diabetic Cardiomyopathy Revisited
Boudina, S., & Abel, E. D. (2007) · Circulation · doi:10.1161/circulationaha.106.679597 · Cited by 1,543
Cellular death, reactive oxygen species (ROS) and diabetic complications
Volpe, C. M. O., Villar-Delfino, P. H., dos Anjos, P. M. F., & Nogueira-Machado, J. A. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0135-z · Cited by 1,166
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803
Quagliaro, L., Piconi, L., Assaloni, R., Martinelli, L., Motz, E., & Ceriello, A. (2003) · Diabetes · doi:10.2337/diabetes.52.11.2795 · Cited by 769
Evidence for Cardiomyopathy in Familial Diabetes Mellitus
Regan, T. J., Lyons, M. M., Ahmed, S. S., Levinson, G. E., Oldewurtel, H. A., Ahmad, M. R., & Haider, B. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108843 · Cited by 728
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Basic Mechanisms of Diabetic Heart Disease
Ritchie, R. H., & Abel, E. D. (2020) · Circulation Research · doi:10.1161/circresaha.120.315913 · Cited by 708
Tsutsui, H., Isobe, M., Ito, H., Ito, H., Okumura, K., Ono, M., Kitakaze, M., Kinugawa, K., Kihara, Y., Goto, Y., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0342 · Cited by 704
Self-citationPalmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679 · cited 1×
“SGLT-2 inhibitors and GLP-1 receptor agonists lowered all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and kidney failure, but GLP-1 receptor agonists had little or no effect on hospitalizations for heart failure [94].”
BackgroundDiabetic Cardiomyopathy: What Is It and Can It Be Fixed?
Dillmann, W. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.314665 · Cited by 669
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Mahabadi, A. A., Berg, M. H., Lehmann, N., Kälsch, H., Bauer, M., Kara, K., Dragano, N., Moebus, S., Jöckel, K.-H., Erbel, R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.062 · Cited by 529
Tong, M., Saito, T., Zhai, P., Oka, S.-I., Mizushima, W., Nakamura, M., Ikeda, S., Shirakabe, A., & Sadoshima, J. (2019) · Circulation Research · doi:10.1161/circresaha.118.314607 · Cited by 498
Russo, I., & Frangogiannis, N. G. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.011 · Cited by 474
Redman, L. M., Smith, S. R., Burton, J. H., Martin, C. K., Il'yasova, D., & Ravussin, E. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.019 · Cited by 472 · cited 1×
“Studies in healthy humans have also shown improved health-related quality of life and reduced oxidative stress in a 2-year 15% calorie-restricted group compared to those in a group without restriction [56].”
BackgroundDeactivation of peroxisome proliferator–activated receptor-α during cardiac hypertrophic growth
Barger, P. M., Brandt, J. M., Leone, T. C., Weinheimer, C. J., & Kelly, D. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9056 · Cited by 464
Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444
Gundewar, S., Calvert, J. W., Jha, S., Toedt-Pingel, I., Yong Ji, S., Nunez, D., Ramachandran, A., Anaya-Cisneros, M., Tian, R., & Lefer, D. J. (2009) · Circulation Research · doi:10.1161/circresaha.108.190918 · Cited by 423
Ceramide is a cardiotoxin in lipotoxic cardiomyopathy
Park, T.-S., Hu, Y., Noh, H.-L., Drosatos, K., Okajima, K., Buchanan, J., Tuinei, J., Homma, S., Jiang, X.-C., Abel, E. D., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800147-jlr200 · Cited by 411
Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart Failure
Katz, S. D., Hryniewicz, K., Hriljac, I., Balidemaj, K., Dimayuga, C., Hudaihed, A., & Yasskiy, A. (2005) · Circulation · doi:10.1161/01.cir.0000153349.77489.cf · Cited by 410
NLRP3 Gene Silencing Ameliorates Diabetic Cardiomyopathy in a Type 2 Diabetes Rat Model
Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., Zhang, M., Zhang, Y., & An, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104771 · Cited by 408
Eurich, D. T., Weir, D. L., Majumdar, S. R., Tsuyuki, R. T., Johnson, J. A., Tjosvold, L., Vanderloo, S. E., & McAlister, F. A. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.000162 · Cited by 341
Chokshi, A., Drosatos, K., Cheema, F. H., Ji, R., Khawaja, T., Yu, S., Kato, T., Khan, R., Takayama, H., Knöll, R., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.060889 · Cited by 296
Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential
Faria, A., & Persaud, S. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.013 · Cited by 295
Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-Activated Protein Kinase
Sasaki, H., Asanuma, H., Fujita, M., Takahama, H., Wakeno, M., Ito, S., Ogai, A., Asakura, M., Kim, J., Minamino, T., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.798561 · Cited by 289
Cardiomyopathy in obesity, insulin resistance and diabetes
Nakamura, M., & Sadoshima, J. (2020) · The Journal of Physiology · doi:10.1113/jp276747 · Cited by 286
Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications
Zeng, C., Wang, R., & Tan, H. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.33568 · Cited by 283
Endothelial Control of Arterial Distensibility Is Impaired in Chronic Heart Failure
Ramsey, M. W., Goodfellow, J., Jones, C. J. H., Luddington, L. A., Lewis, M. J., & Henderson, A. H. (1995) · Circulation · doi:10.1161/01.cir.92.11.3212 · Cited by 279
Decreased Sarcoplasmic Reticulum Activity and Contractility in Diabetic db/db Mouse Heart
Belke, D. D., Swanson, E. A., & Dillmann, W. H. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3201 · Cited by 252
Cardiac Autonomic Neuropathy in Diabetes Mellitus
Agashe, S., & Petak, S. (2018) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-14-4-251 · Cited by 239
Lipotoxicity in type 2 diabetic cardiomyopathy
van de Weijer, T., Schrauwen-Hinderling, V. B., & Schrauwen, P. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr212 · Cited by 235
Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
Matthews, V. B., Elliot, R. H., Rudnicka, C., Hricova, J., Herat, L., & Schlaich, M. P. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001434 · Cited by 222
Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes
Aguilar, D., Bozkurt, B., Ramasubbu, K., & Deswal, A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.049 · Cited by 217
Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects
Razavi Nematollahi, L., Kitabchi, A. E., Stentz, F. B., Wan, J. Y., Larijani, B. A., Tehrani, M. M., Gozashti, M. H., Omidfar, K., & Taheri, E. (2009) · Metabolism · doi:10.1016/j.metabol.2008.10.018 · Cited by 210
Tuleta, I., & Frangogiannis, N. G. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166044 · Cited by 208
Advanced glycation end products: role in pathology of diabetic cardiomyopathy
Bodiga, V. L., Eda, S. R., & Bodiga, S. (2014) · Heart Failure Reviews · doi:10.1007/s10741-013-9374-y · Cited by 207
Philippaert, K., Kalyaanamoorthy, S., Fatehi, M., Long, W., Soni, S., Byrne, N. J., Barr, A., Singh, J., Wong, J., Palechuk, T., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053350 · Cited by 204
Castagno, D., Baird-Gunning, J., Jhund, P. S., Biondi-Zoccai, G., MacDonald, M. R., Petrie, M. C., Gaita, F., & McMurray, J. J. V. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.030 · Cited by 190
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
Sano, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.12.004 · Cited by 188
The Effects of SGLT2 Inhibitors on Lipid Metabolism
Szekeres, Z., Toth, K., & Szabados, E. (2021) · Metabolites · doi:10.3390/metabo11020087 · Cited by 187
Groop, P.-H., Forsblom, C., & Thomas, M. C. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0046 · Cited by 182
Diabetic cardiomyopathy: where we are and where we are going
Lee, W.-S., & Kim, J. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.208 · Cited by 163
Basu, R., Oudit, G. Y., Wang, X., Zhang, L., Ussher, J. R., Lopaschuk, G. D., & Kassiri, Z. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00452.2009 · Cited by 161
Andersson, C., Olesen, J. B., Hansen, P. R., Weeke, P. E., Norgaard, M. L., Jørgensen, C. H., Lange, T., Abildstrom, S. Z., Schramm, T. K., Vaag, A. A., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1906-6 · Cited by 154
Postprandial hyperlipidemia as a potential residual risk factor
Nakamura, K., Miyoshi, T., Yunoki, K., & Ito, H. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.12.001 · Cited by 129
Self-citationCardiac Adiposity and Global Cardiometabolic Risk New Concept and Clinical Implication
Shimabukuro, M. (2008) · Circulation Journal · doi:10.1253/circj.cj-08-1012 · Cited by 127
Mitophagy in Diabetic Cardiomyopathy: Roles and Mechanisms
Zheng, H., Zhu, H., Liu, X., Huang, X., Huang, A., & Huang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.750382 · Cited by 116
Late sodium current: A mechanism for angina, heart failure, and arrhythmia
Makielski, J. C. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.006 · Cited by 106
Ng, K., Lau, Y., Dhandhania, V., Cai, Z., Lee, Y.-K., Lai, W., Tse, H., & Siu, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-33293-2 · Cited by 93
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
Martens, P., Mathieu, C., & Verbrugge, F. H. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0522-x · Cited by 90
Diabetes-Related Heart Failure: Does Diabetic Cardiomyopathy Exist?
Bando, Y., & Murohara, T. (2014) · Circulation Journal · doi:10.1253/circj.cj-13-1564 · Cited by 84
den Bergh, A. V., Vanderper, A., Vangheluwe, P., Desjardins, F., Nevelsteen, I., Verreth, W., Wuytack, F., Holvoet, P., Flameng, W. J., Balligand, J., et al. (2007) · Cardiovascular Research · doi:10.1093/cvr/cvm001 · Cited by 83
Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?
Packer, M. (2018) · Circulation Research · doi:10.1161/circresaha.118.312673 · Cited by 80
Ejiri, K., Miyoshi, T., Kihara, H., Hata, Y., Nagano, T., Takaishi, A., Toda, H., Nanba, S., Nakamura, Y., Akagi, S., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015103 · Cited by 79
Self-citationGobbo, L. C. D., Song, Y., Poirier, P., Dewailly, É., Elin, R. J., & Egeland, G. M. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-23 · Cited by 77
Oxidative Stress Signaling Mediated Pathogenesis of Diabetic Cardiomyopathy
Tang, Z., Wang, P., Dong, C., Zhang, J., Wang, X., & Pei, H. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5913374 · Cited by 77
Protective role of hydrogen sulfide against diabetic cardiomyopathy via alleviating necroptosis
Gong, W., Zhang, S., Chen, Y., Shen, J., Zheng, Y., Liu, X., Zhu, M., & Meng, G. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.01.028 · Cited by 67
Rotkvić, P. G., Planinić, Z., Pršo, A.-M. L., Šikić, J., Galić, E., & Rotkvić, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115973 · Cited by 66
FESC, F. E. O. A. D.-4. I. O. L. V. D. D. I. P. W. T. 2. D. A. D. C. (. S. I., Oe, H., Nakamura, K., Kihara, H., Shimada, K., Fukuda, S., Takagi, T., Miyoshi, T., Hirata, K., Yoshikawa, J., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0242-z · Cited by 64
Self-citationPal, P. B., Sonowal, H., Shukla, K., Sk, S., & Ramana, K. V. (2017) · Endocrinology · doi:10.1210/en.2017-00294 · Cited by 64
Nie, J., Duan, Q., He, M., Li, X., Wang, B., Zhou, C., Wu, L., Zheng, W., Chen, C., Wang, D. W., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27791 · Cited by 61
Rahman, A., Fujisawa, Y., Nakano, D., Hitomi, H., & Nishiyama, A. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12725 · Cited by 53
Sano, M., Chen, S., Imazeki, H., Ochiai, H., & Seino, Y. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12726 · Cited by 52
Wang, Z. V., & Hill, J. A. (2015) · Circulation · doi:10.1161/circulationaha.115.015357 · Cited by 47
Takata, T., & Isomoto, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094374 · Cited by 39
Jin, W. L., Azuma, K., Mita, T., Goto, H., Kanazawa, A., Shimizu, T., Ikeda, F., Fujitani, Y., Hirose, T., Kawamori, R., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2141-5 · Cited by 35
Kimura, T., Nakamura, K., Miyoshi, T., et al. (2019) · International Heart Journal · doi:10.1536/ihj.18-392 · Cited by 31
Self-citationYoshida, M., Nakamura, K., Miyoshi, T., Yoshida, M., Kondo, M., Akazawa, K., Kimura, T., Ohtsuka, H., Ohno, Y., Miura, D., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01132-2 · Cited by 17
Self-citationDiabetic cardiomyopathy: factual or factoid?
Quinaglia, T., de Oliveira, D. C., Matos‐Souza, J. R., & Sposito, A. C. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.1.69 · Cited by 16
Yoshida, M., Nakamura, K., Miyoshi, T., Yoshida, M., Kondo, M., Akazawa, K., Kimura, T., Ohtsuka, H., Ohno, Y., Miura, D., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01181-7 · Cited by 10
Self-citationSugawara, R., Sugiyama, H., Nakamura, K., Tohgi, K., Hongo, T., Tsuchiya, M., Momoki, N., Nose, S., Yutani, C., Ikeda, Y., et al. (2021) · International Heart Journal · doi:10.1536/ihj.20-537 · Cited by 7
Self-citationYanagawa, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3014w · Cited by 6
Volpe, M., & Patrono, C. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab715 · Cited by 6
Cited by
Alobaid, S. M., Alshahrani, R. M., Alonazi, A. S., Alrasheed, N. M., Alamin, M. A., Alshammari, T. K., Bin Dayel, A. F., Elnagar, D. M., Alotaibi, R. R., Almuthnabi, L. A., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17030374 · Cited by 13
“…GLP1R is pivotal for identifying novel therapeutic targets and for devising strategies DCM, an unfavorable condition resulting from type 2 diabetes [31], was modeled in this study using the STZ/high-fat diet (HFD) model [32]. with potential clinical applications in diverse cardiovascular diseases,…”
Method
Metadata
- Authors
- Nakamura, K., Miyoshi, T., Yoshida, M., Akagi, S., Saito, Y., Ejiri, K., Matsuo, N., Ichikawa, K., Iwasaki, K., Naito, T., Namba, Y., Yoshida, M., Sugiyama, H., & Ito, H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-03-25
- Volume
- 23
- Issue
- 7
- Pages
- 3587
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4220968668
- Cited by
- 268
- References
- 93
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.